These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36630749)

  • 21. The recency ratio as predictor of early MCI.
    Bruno D; Koscik RL; Woodard JL; Pomara N; Johnson SC
    Int Psychogeriatr; 2018 Dec; 30(12):1883-1888. PubMed ID: 29667564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
    Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
    J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Forgetting Rates on the Recency Portion of a Word List Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease.
    Turchetta CS; De Simone MS; Perri R; Fadda L; Caruso G; De Tollis M; Caltagirone C; Carlesimo GA
    J Alzheimers Dis; 2020; 73(4):1295-1304. PubMed ID: 31903988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Montreal Cognitive Assessment in Mild Cognitive Impairment: Relationship with Cerebrospinal Fluid Biomarkers and Conversion to Dementia.
    Bernardes C; Lima M; Duro D; Silva-Spínola A; Durães J; Tábuas-Pereira M; Baldeiras I; Freitas S; Santana I
    J Alzheimers Dis; 2023; 96(3):1173-1182. PubMed ID: 37927268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of story-recall metrics to predict hippocampal volume in older adults with and without cognitive impairment.
    Jauregi Zinkunegi A; Bruno D; Betthauser TJ; Langhough R; Asthana S; Chin NA; Hermann BP; Johnson SC; Mueller KD
    Clin Neuropsychol; 2024 Feb; 38(2):453-470. PubMed ID: 37349970
    [No Abstract]   [Full Text] [Related]  

  • 33. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer's Disease.
    Mueller KD; Du L; Bruno D; Betthauser T; Christian B; Johnson S; Hermann B; Koscik RL
    Front Psychol; 2022; 13():908651. PubMed ID: 35832924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
    Barba L; Abu Rumeileh S; Bellomo G; Paolini Paoletti F; Halbgebauer S; Oeckl P; Steinacker P; Massa F; Gaetani L; Parnetti L; Otto M
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):83-86. PubMed ID: 35944974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis.
    Yoong SQ; Lu J; Xing H; Gyanwali B; Tan YQ; Wu XV
    Ageing Res Rev; 2021 Dec; 72():101491. PubMed ID: 34688925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.